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Abstract 
 
Background/Aims: Several gene variants conveying modestly increased risk for 
disease have been described for colorectal cancer. Patient acceptance of gene variant 
testing in clinical practice is not known.  We evaluated the potential impact of 
hypothetical colorectal cancer associated gene variant testing on quality of life, health 
habits, and cancer screening behavior. 
Methods: First-degree relatives of colorectal cancer patients and controls from the 
Seattle Colorectal Cancer Familial Registry were invited to participate in a web-based 
survey regarding colorectal cancer risk gene variant testing.  
Results: 310 relatives and 170 controls completed the questionnaire. Quality of life for 
the hypothetical carrier state was modestly but non-significantly lower than current 
health after adjustment for sociodemographic and health factors.  In the positive test 
scenario, 30% of respondents expressed willingness to change their diet, 25% would 
increase exercise, and 43% would start colorectal cancer screening. The proportions 
willing to modify these habits did not differ between groups. 
Conclusions: Testing for gene variants associated with colorectal cancer risk may not 
influence quality of life, but may impact health habits and screening adherence. 
Changing behaviors as a result of testing may help to reduce cancer incidence and 
mortality, particularly among those at higher risk for colorectal cancer. 
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INTRODUCTION 
Colorectal cancer is the third most common cancer and the third leading cause of 
cancer mortality in the United States [1]. Approximately 10% to 15% of individuals with 
colorectal cancer have an affected family member, and a small fraction of these 
individuals have cancer family syndromes with known mutations [2].  For the rest, a 
combination of environmental and genetic factors plays a role in the development of the 
colorectal cancer [3].  
A number of studies have identified high prevalence, low penetrance gene 
variants (polymorphisms, haplotypes) that appear to be associated with a somewhat 
higher risk of developing colorectal cancer [4-7].  Although persons are not currently 
tested for these variants in clinical practice, the prospect of using genetic and 
environmental information to tailor screening and modify environmental exposures as a 
means of prevention is a conceptual cornerstone of personalized medicine as applied to 
cancer [8, 9]. A test for these gene variants would differ in an important way from the 
cancer susceptibility tests currently in clinical use, such as BRCA [10] and Lynch 
syndrome testing [11]:  rather than identifying rare persons with very high lifetime risk, 
the gene variant test would predict a moderate but clinically meaningful increase in 
cancer risk among as many as 10% to 15% of the population.  As a result, the test could 
be considered for population screening.   
We conducted a population-based survey to determine how a hypothetical test 
for gene variants associated with moderately increased colorectal cancer risk might 
influence individuals’ health-related quality of life (HRQOL), cancer worry, health habits, 
and screening behavior.  In addition, to determine whether an individual’s family history 
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of colorectal cancer (and thus their current estimate of cancer risk) modified these 
issues, we compared participants without colorectal cancer who did or did not have a 
family history of colorectal cancer.  
Our first hypothesis was that an individual’s perceived quality of life would fall 
after being informed that he or she carried a cancer-associated gene variant. We also 
hypothesized that being told one is a carrier would have a greater impact on perceived 
HRQOL for persons with experience caring for a family member with cancer than for 
those who had no such experience. Finally, we postulated that relatives of colorectal 
cancer patients would be more likely to modify their behavior—specifically their diet, 
exercise habits, and adherence to colorectal cancer screening recommendations—in 
response to information about their risk status as determined by testing for moderate 
risk genetic variants than those who have no family history of colorectal cancer. 
 
MATERIALS AND METHODS 
Population Sample  
Study participants were recruited from the Seattle Colorectal Cancer Family 
Registry (C-CFR) to participate in this survey concerning HRQOL and the behavioral 
impact of genetic testing for high prevalence, low penetrance gene variants. The C-CFR 
is a National Cancer Institute-supported consortium of six international sites initiated in 
1997, dedicated to the establishment of a comprehensive collaborative infrastructure for 
interdisciplinary studies in the genetics and genetic epidemiology of colorectal cancer 
[12]. The cooperating institutions collect epidemiological information and laboratory 
specimens from affected families and relatives at all risk levels for colorectal cancer. 
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The Seattle C-CFR ascertains incident colorectal cancer cases from the Seattle 
metropolitan area through the Western Washington Surveillance, Epidemiology, and End 
Results (SEER) program. All individuals ages 18-74 diagnosed with colorectal cancer in 
the Western Washington SEER region (except in situ cases) were invited to enroll in the 
C-CFR.  First-degree relatives of these cancer patients (parents, siblings, and children) 
were then contacted to participate in the registry. Finally, for each first-degree relative of 
the enrolled cases, the C-CFR identified a control participant without a family history of 
colorectal cancer, selected from Washington State Department of Licensing (DOL) 
records. These DOL controls were then matched to the first-degree relatives based on 
age and sex. The C-CFR database of cancer cases, first-degree relatives, and DOL 
controls are re-contacted periodically to assess cancer incidence and vital status.  
 
Theoretical Model  
Theoretical models of health behavior suggest that perceptions of risk, 
seriousness, and control are factors that influence the adoption of health-related 
behaviors [13-15]. Applying these models to the domain of genetic susceptibility for 
cancer, researchers have shown that these factors are important for persons carrying 
high risk mutations such as the BRCA1/2 and HNPCC mutations [16-19]. In the area of 
genetic testing, theoretical models suggest that emotional factors such as cancer worry 
can motivate action such as preventive maneuvers to mitigate perceived risk [20-22].  
However, empirical studies suggest that extreme distress, as might be experienced by 
some individuals carrying genetic mutations that place them at very high risk for cancer, 
may result in passive coping and avoidance of health improving strategies such as 
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screening [23-26]. It is less clear how perceptions regarding the level of risk might 
influence cancer worry and health behaviors, particularly for persons whose cancer risk 
is only modestly higher than the population, such as those with a single affected family 
member. This issue is particularly salient to the area of polymorphism testing.   
 
Sampling and Survey Procedures 
Drawing from the C-CFR population, first-degree relatives of colorectal cancer 
patients (hereafter referred to as “relatives”) and those without a family history of 
colorectal cancer (hereafter referred to as “controls”), as described above were invited 
to participate in the survey. To reflect a possible range of age where gene variant 
screening might begin, relatives and controls between the ages of 20 and 65 from the 
C-CFR population were invited to participate in the survey (n=2160). All persons in this 
age group were invited except relatives with family histories that were consistent with 
Lynch syndrome or Adenomatous Polyposis Coli (n=234). 
Relatives and controls were mailed an invitation letter that included a description 
of the study, security and confidentiality materials, and instructions for accessing a 
study-specific web site (using a unique log-in and password) that contained further 
information about the study and the survey itself. The mailing also included a response 
card with a self-addressed stamped envelope. Individuals could decline to participate 
either through the study web site or by returning the card after checking the “decline to 
participate” box. The letter stated that a study coordinator would call the recipient to 
inquire about interest and to answer questions if the participant did not complete the 
survey, return the response card, or contact the study office within three weeks.  
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In past studies, we have found that follow-up phone calls greatly improve 
participation and reduce errors completing quality-of-life surveys [27]. The study 
coordinator called potential participants if they did not respond to the initial mailing 
within three weeks’ time. During the phone call, the study coordinator described the 
method of completing the survey (i.e., via the Internet), and offered options for 
completing the survey to those who did not have a computer or internet access at home 
(e.g., public library). Those who declined to participate during the telephone call were 
thanked but not contacted further.  
 
Survey Content 
The survey was administered and completed on a study-dedicated secure 
website. Prior to the question portion of the survey, participants were given information 
on colorectal cancer, including risk factors, screening modalities, recommended 
screening schedules, and the likely relationship between genes and risk for colorectal 
disease, including the difference between modest risk posed by the gene variants in the 
hypothetical test and higher risk for individuals with highly penetrant mutations such as 
those associated with Lynch Syndrome. Specifically, persons were told that in the 
general population, the lifetime risk for developing colorectal cancer is 4%, and that a 
person carrying a polymorphism that raised the risk by 50% would mean their lifetime 
risk would be 6%. 
In the first section of the survey, participants completed demographic questions, 
the EQ-5D, family history questions, a question asking them to estimate their risk for 
developing colorectal cancer, colorectal cancer screening history questions, lifestyle 
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and diet questions, and a visual analogue scale (VAS) for rating their current HRQOL 
on a scale of 0 to 100.  The EQ-5D is a standardized instrument for use as a measure 
of HRQOL. Applicable to a wide range of health conditions and treatments, it provides a 
simple descriptive profile and a single index value for health status, ranging from 0 to 1 
[28]. Because family experience with cancer can influence both perceptions of cancer 
risk and screening behavior [29-32], respondents were also asked whether they have 
cared for a family member with any type of cancer, and if so, the extent of their 
involvement in that family member’s cancer treatment. 
Participants also completed an interactive version of the standard gamble 
interview [33].  The standard gamble is a method of assigning utilities for a given health 
state. Utilities are a measure of an individual’s preference for a particular health state, 
reflecting perceived HRQOL in that state. The health state may be one the individual 
has experienced or an imagined state based on a description provided by the 
interviewer. Details describing the theory and methods of the standard gamble are 
available in reference texts and manuscripts [34, 35]. Briefly, the respondent is asked to 
choose one of two options: (1) a chronic health state that would continue indefinitely, 
and; (2) a gamble that results in one of two outcomes, a certain amount of life in ideal 
health or immediate painless death. The probability of immediate death in the gamble is 
varied systematically until the respondent is indifferent between the certain health state 
and the gamble.  The risk of immediate death in the gamble at the point of indifference 
is then translated to a utility score, which can range from 0 (death) to 1 (ideal health). In 
this survey, the chronic health state of interest was one where the respondent had 
knowledge that he or she carried a gene variant that was associated with an increased 
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risk for colorectal cancer.  Respondents were also asked to rate their current “chronic” 
health. For both the gene variant and the participant’s current health, patients were 
presented with a choice of remaining in that health state or selecting a gamble between 
ideal health and immediate death. 
In the second section of the survey the participant was presented with a 
hypothetical scenario stating that their doctor ordered a blood test for a polymorphism 
that provided information about their risk for colorectal cancer. Participants were asked 
to rate their own risk for developing colorectal cancer and then were told to imagine a 
polymorphism test that raised their risk by 50%. The numerical implications of a 50% 
higher risk on their baseline estimate were presented to them. After describing this test 
and what the results would mean, they were then asked to consider two possible 
outcomes: (1) the results indicated they were a polymorphism carrier, and; (2) the 
results indicated they were not a carrier. There were separate questions following each 
possible outcome asking the respondent whether—after knowing he results of the test—
he or she would change diet, exercise habits, and (for those who were eligible for 
screening by age) colorectal cancer screening behaviors . Participants were also asked 
about whether knowing the result of the test (positive and negative) would influence 
their overall cancer worry.  
Participants were able to log in and out of the password-protected website, thus 
allowing them to complete the survey as their schedules permitted them to do so. 
Participants also had access to a contact area on a sidebar of the web display, which 
allowed them to send questions or comments via e-mail to the study coordinator. 
Additionally, the web site and the invitation letter included contact information for 
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assistance by mail, telephone, or e-mail from the study coordinator. The study 
coordinator responded to patient queries by telephone or e-mail within 24 hours during 
weekdays. 
If participants did not answer a particular question, the survey automatically 
directed the participant to that question with a prompt to complete the question. If a 
participant wanted to refuse to answer a question, then she was directed to choose the 
option “I prefer to not answer the question” and then continue. All participant responses 
and survey activity were recorded on a secure server in real time and transmitted to the 
study coordinator. 
We used registry information that was available for the C-CFR sample population 
to identify respondent characteristics that predicted survey non-response (either active 
refusal or failure to complete the survey) after excluding those who were deemed 
ineligible as the result of illness or other factors leading to inability to complete the 
survey. Factors in the logistic regression model (1=non-response) included age, sex, 
race, marital status, urban vs. rural residence, educational attainment, and whether the 
individual was from the relative or control group. Race as defined by the participant was 
previously gathered by the C-CFR survey.  
Because HRQOL data are typically highly skewed, we used nonparametric tests 
to evaluate the unadjusted data stratified by respondent group. We calculated average 
utility weights for each health state (current health, carrier of gene variant) for the entire 
sample, then after stratifying by risk group (relative or control). We compared standard 
gamble utility weights, EQ-5D summary scores and VAS ratings for relatives versus 
persons with no family history using the Wilcoxon two-sample test. The standard 
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gamble utility measure compared the current health and “gene variant” states for the 
relative and control groups.  
Spearman’s test was used to evaluate the correlation between an individual’s 
assessment of their lifetime cancer risk and (1) being a relative or a control and (2) 
receipt of colorectal cancer screening within recommended time frame. 
Generalized linear models were used to determine whether patient factors 
modified the effects of the hypothetical gene variant carrier status on health state 
utilities, cancer worry, health habits, and intentions towards screening compared to 
reported levels prior to the gene variant testing scenario.  The dependent variables for 
each of the regression models were as follows:  
(1) health state utilities—this variable included both the participant’s utility value 
for current health and for the gene variant carrier state, derived from the standard 
gamble;  
(2) cancer worry in response to gene variant test result (positive test: -2 to 0 with 
-2=very worried, 0=no worry; negative test: -2 to 2, -2 = very worried, 2=very relieved);   
(3) health habits: participant’s stated degree of change reported in exercise to 
test results (positive test: exercise 0 to 2 with 0=no change, 2=“exercise a lot more”; 
negative test: -1 to 2; -1=“exercise less”, 2=“exercise a lot more”) and diet in response 
to being told of a positive or negative gene test scenario (positive and negative test: diet 
0 to 2 with 0=no changes, 2=big changes);  
(4) colorectal cancer screening intent as a result of the test (0=“no, I don’t get 
screened and wouldn’t plan to change now,” 1=“yes, I don’t get screened as often as 
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recommended and would see my doctor about screening” or “I have never been 
screened and would see my doctor about screening”).  
Independent variables for all models included age, gender, race (white or 
nonwhite), lower education status (high school or less), marital status, relative vs. 
control, accompanying a family member through cancer treatment or speaking 
frequently with them during treatment (yes/no).  
 
 
RESULTS 
We mailed invitations to 1294 relatives and 866 controls. A total of 397 (18.4%) 
study participants were not reached despite the initial mailing and five follow-up phone 
calls. Of those who were successfully contacted, 947 (43.8%) declined participation via 
the self-addressed postcard or at the follow-up phone call. An additional 336 (15.6%) 
respondents were deemed ineligible after contact by the study coordinator for one of the 
two reasons: (1) the individual was unable or unwilling to access the internet; (2) the 
respondent had a severe illness that prevented completion of the survey.  After 
answering the family history questions, 20 people in the control group revealed a family 
history of colorectal cancer which was unknown at the time of their initial C-CFR 
interview and were thus re-categorized as relatives. After reassigning those 20 
participants to the relative category, as they now have a family history of colorectal 
cancer, a total of 310/1314 (23.6%) relatives and 170/846 (20.1%) controls completed 
the survey. 
We conducted a logistic regression of all relatives and controls to examine 
factors associated with non-response. We first excluded those who were found to be 
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ineligible after approach. Among eligible participants male sex and African American 
race (vs. white) were significantly associated with survey non-response. College and 
graduate school education was associated with higher likelihoods of survey response. 
Tables 1 and 2 list demographic characteristics, health behaviors, and HRQOL 
responses of the respondents, stratified by whether they were a relative or control. 
Compared to controls, female relatives were significantly younger, less highly educated, 
and reported a significantly higher average number of relatives with colorectal cancer 
and any cancer.  The proportion of women was not statistically different in the two 
groups.   
A higher proportion of controls compared to relatives reported either 
accompanying a family member through treatment for any cancer or speaking 
frequently with them during treatment (Table 1).  Table 1 also shows individual’s ratings 
of their current HRQOL, as measured by EQ-5D, VAS, and standard gamble scores. 
There was no significant difference between relatives and controls on any of these 
summary measures of health status.  There also was no significant difference in diet, 
alcohol use, or tobacco use between groups. Relatives were significantly more likely to 
have had colorectal cancer screening, but were less likely to exercise regularly. 
Relatives generally reported a higher estimated lifetime risk of developing colorectal 
cancer than controls, most notably among persons between the ages of 46 and 55 
(estimated lifetime risk: 29% and 9%, respectively, p<0.0001).  
Adjusting for participant age, individuals’ assessments of their lifetime cancer risk 
was significantly higher for relatives vs. controls and significantly associated with receipt 
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of colorectal cancer screening within recommended time frame (p<0.0001 in both 
instances). 
Tables 3 and 4 summarizes responses to the hypothetical questions regarding 
worry/relief, informing friends and family, and intent to modify lifestyle and screening 
behavior after learning gene variant carrier status.  
 
Positive Test (Carrier) Scenario 
Cancer Worry: Under the scenario of having a cancer-associated gene variant, 
69 percent of all respondents recorded that they would be “somewhat” worried by the 
results; 18 percent would be “very” worried. The proportion who stated they would 
remain “very worried” at 1 year following the test was not significantly different from the 
immediate scenario. There was no significant difference in the percentage of relatives 
who reported being “very worried” at a positive gene variant result compared to controls. 
Among relatives, there was no relationship between number of relatives with colorectal 
cancer and their degree of worry in response to the scenario of having a positive gene 
variant result (p=0.84). Among relatives and controls, the level of a participant’s 
involvement with a family member with cancer and their degree of worry in response to 
the scenario of having a cancer-associated gene variant did show a statistically 
significant association (p=0.008) with higher worry for those with greater involvement.  
Willingness to tell others about test results: Overall, nearly 88% of respondents 
reported that they would tell their spouse if they had a positive test; approximately three-
fourths would tell their siblings. More than 50% would tell children, parents, or close 
friends about the results. Less than 3% said they would tell “no one” about the result. 
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There was no significant difference between relatives and controls in terms of 
willingness to tell others about the test result. 
Intent to change diet, exercise, and colorectal cancer screening: About 25% of all 
participants stated they would exercise “a lot” more and 30% would make “big changes” 
in their diet. There was no significant difference between relatives and controls in stated 
intent to change these behaviors. Fifty percent of all participants stated that they already 
were receiving regular colorectal cancer screening, but significantly more relatives had 
already had screening than controls (p<0.001). Among those who did not currently 
report screening, 43% stated that they would start. Controls were significantly more 
likely to state intent to start screening than were relatives (p=0.03).  
 
Negative Test (Non-carrier) Scenario 
Cancer Worry: Under the scenario of a negative gene variant test, 46% of all 
respondents said they would be “a little relieved;” 33% said they would be “very 
relieved.” There was no significant difference between relatives and controls.  
Willingness to Tell Others about the Test Result: As with the positive result, most 
stated that they would tell their spouse and siblings about a negative test result. Fewer 
than 50% would tell their children, parents or close friends. There was no significant 
difference between relatives and controls in terms of willingness to inform others. 
Intent to Change Diet, Exercise, and Colorectal Cancer Screening: Fewer 
participants indicated that they would make substantial differences in their diet and 
exercise if the gene variant test came back negative: 60% would not change their diet 
and 64% would not change their exercise. Only 5% indicated they would exercise “a lot” 
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more and only 2% would make “big changes” in their diet. A smaller proportion of those 
who were not current regular screeners indicated they would seek screening (26%) 
compared to the test positive scenario. There was no difference in responses to the 
diet, exercise and screening questions for relatives and controls.  
 
Standard Gamble Interview Results: Current Health vs. Carrier State 
Relatives’ and controls’ general health state utilities, as measured by the 
standard gamble, were similar.  Both relatives and controls had modestly lower utility 
scores for the gene variant state compared to current; the difference was significant 
only for relatives. (Controls 0.89 vs. 0.88 p=0.11; Relatives 0.90 vs. 0.88, p=0.02). 
When standard gamble scores were adjusted for respondent characteristics on 
multivariate analysis, the gene variant state was not significantly associated with lower 
utility scores.  
 
Respondent Factors Associated with Changes in Health Habits and Screening following 
Gene Variant Testing 
 Generalized linear models were used to determine whether patient factors 
modified the effects of the hypothetical gene variant carrier status on overall health 
state, cancer worry, health habits, and intentions towards screening compared to 
reported levels prior to the gene variant testing scenario.  In the gene variant positive 
scenario, no single factor was significantly associated with changes in worry, with 
intentions to change exercise or diet, or with intentions to adhere to screening 
recommendations. Being told one did not have a cancer-associated gene variant was 
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also not significantly associated with relief or worry, was not significantly associated with 
intentions to change exercise, diet, or adherence to screening recommendations.  For 
each of these models, being a relative of a cancer patient did not influence the 
significance of the associations.  
 
DISCUSSION 
 Drawing from a population-based survey, we conducted interviews to determine 
how a hypothetical gene variant test for detecting persons with modestly higher 
colorectal cancer risk would influence an individual’s overall HRQOL, health habits and 
screening behaviors. In adjusted analysis a scenario of testing positive did not impact 
cancer worry or overall quality of life. Most participants said that a positive test result 
would motivate them to make improvements in their diet and exercise habits. The great 
majority of those who were eligible but were not receiving regular colorectal cancer 
screening said that a positive test would motivate them to pursue screening. There was 
no significant difference in responses among relatives of colorectal cancer patients 
compared to controls. 
Using gene variant testing to identify persons at modestly higher risk for 
colorectal cancer has potential benefits compared to family history screening. First, lay 
persons often have limited knowledge about their risk, and physicians’ collection and 
assessment of family history information is often suboptimal [36-38]. Blood or saliva 
tests would be simpler to obtain and potentially more accurate than a person’s 
recollection of their family history. Further, testing may capture risk status that might not 
be elicited using standard family history questions.  
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Second, screening rates for colorectal cancer have been rising, but are still 
substantially below recommendations [39]. Screening rates are also suboptimal among 
people with a family history of colorectal cancer, many of whom are unaware of their 
increased risk or eligibility for earlier screening [40, 41]. A physician recommendation to 
screen is a strong predictor of screening in both average risk persons and those with a 
family history of colorectal cancer, and uptake of screening [42-45]. Gene variant testing 
could assist physicians to provide tailored screening recommendations. Genetic testing 
may even be cost effective if the results improved cancer screening rates among those 
at highest risk for disease [46]. 
Despite these potential benefits, there are several unresolved issues and 
potential concerns with population screening to obtain genetic information about cancer 
risk. The concern we address here is how knowledge of ones’ genetic status—
particularly for relatively common variants that convey modestly increased risk—would 
influence health state, cancer worry, and overall quality of life. The issue is important, 
since mass screening gene variant programs would identify far more persons who 
would be classified as carriers compared to mutation testing, yet far fewer would 
actually develop disease because the low penetrance of most variants.  
Although several studies have evaluated the impact of testing for rare genetic 
mutations on quality of life and health-related behaviors [19, 26, 47-51], to our 
knowledge this is the first study that has evaluated these issues for gene variants 
associated with modest disease risks. The results suggest that individuals anticipate 
that gene variant testing will motivate them to make improvements in their health-related 
habits and screening. A substantial proportion of respondents noted that the test would 
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create cancer worry, particularly if it was positive. In contrast, the impact on overall 
quality of life—as measured by the standard gamble survey—was negligible. It is not 
possible to determine whether this potential contradiction is due to insensitivity in the 
global measure of HRQOL (utility value) to the test result, or because patient cancer 
worry following the test result, while real, has little substantive impact on an individual’s 
overall sense of well being.   An important issue for further study is whether DNA-based 
testing generates more cancer worry than comparable risk information conveyed on the 
basis of family history.   
We note several limitations to this analysis. First, our overall response rate to this 
internet based survey was low, and those who did respond were of higher 
socioeconomic status than the general population or that of the parent study. Although 
the internet is now nearly ubiquitous, and Washington State ranks fourth in the United 
States in terms of households with computers (72%) and home internet access (63%), 
access to free or very low cost internet services outside of the home is still limited (e.g., 
at public libraries)[52]. Cost and lack of familiarity with computers are relative barriers 
for persons with low educational attainment and/or low incomes. Thus, although 
sampling was population based, respondents to this survey do not necessarily 
represent the overall population makeup of the region.  
Second, the scenario was hypothetical. Historically, individuals’ response to 
hypothetical genetic testing scenarios—for example, willingness to be tested—has not 
corresponded to actual testing experience [53]. Several features of hypothetical case 
scenarios have been identified as increasing a realistic response, including population-
based recruitment, immediacy of the testing scenario, a range of response choices, an 
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accessible and understandable description of testing based on preliminary data, and 
theory-based content [53]; our testing scenario included all of these features.  In 
addition, our focus on response to test results, rather than interest in testing per se, 
allowed us to use methodology validated in other studies of health care preferences. 
Third, the responses to the negative test bias may have been influenced by anchoring 
bias based on the respondents given to the positive test scenario, since the latter was 
presented first to all respondents.  Finally, we tailored the response options for worry 
and exercise based on logical constructs for each scenario, such that certain responses 
were not available for some health states (e.g., “very relieved” was not a response 
option for the gene variant carrier state). If some respondents had wished to respond in 
differently than the available response options, our results would be biased. 
It is known that in the case of some mutations with high penetrance, providing 
people with genetic information on risk may not increase their motivation to change 
behavior and in some cases may decrease motivation [54]; our data suggesting 
motivation to change behavior cannot therefore be interpreted as predicting behavioral 
change, but we believe they indicate a potential for utilizing risk knowledge to 
encourage change, particularly for interventions such as screening that may be affected 
by physicians’ recommendations. Third, genetic testing in general, and high prevalence, 
low penetrance variants in particular, are conceptually abstract concepts that may be 
difficult for lay persons to understand. Our survey was designed and tested for clarity 
and ease of understanding, yet it is possible that the information was still difficult to 
grasp for some respondents. One of the advantages of an internet survey is that it 
allowed us to monitor early on for logic errors in survey responses that would have 
 20
signaled problems with understanding (e.g., reporting more cancer worry after a 
negative vs. positive test result). We did not detect such issues with this survey. The 
method also offered respondents the opportunity to stop and ask questions before 
continuing, perhaps improving the rate of usable responses and avoiding “respondent 
questionnaire fatigue.” 
Testing for gene variants associated with moderate disease risks is not currently 
part of standard medical practice. Our survey suggests that a test that is established to 
have true clinical utility may be accepted by patients, although the impact on feelings of 
worry is concerning. Furthermore, positive results may motivate beneficial health 
behaviors and negative results are not likely to discourage them. Nevertheless, a “go 
slow” approach is advisable with implementation of any genetic screening test. Genetic 
tests for rare mutations such as cancer family syndromes have generally not been 
shown to substantively affect most people’s overall quality of life in the long term, even 
among those who test positive [23, 26, 48, 55, 56]. One reason may be that persons 
from affected families are usually aware of their increased risk before testing. Patients 
without family histories would often face a “surprise” of being told that they are at risk in 
a scenario of testing for common gene variants, since the prevalence of variants will be 
high even though the penetrance is lower than mutations. Patients will need to be 
counseled about the limited implications of a positive test. 
If testing of this kind is adopted into clinical practice, research will be needed that 
informs practitioners about the meaning of the results, how to convey the results, and 
how to minimize potential misinterpretation of the results by patients. For example, it 
would be important for health professionals to convey to patients that a negative test 
 21
result does not necessarily “negate” a positive family history; that is, screening is still 
needed.  
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Table 1. Demographics and Characteristics of Respondents 
 
 No Family 
History 
N=170 (%) 
Relatives 
N = 310 (%) 
Total 
N=480 (%) 
Demographics    
Male 67 (39) 116 (37) 183 (38) 
Average Age, Male 51.1 48.6 49.5 
Average Age, Female** 52.9 47.0 49.1 
Race    
  White 160 (94) 288 (93) 448 (93) 
  Non-white 10 (6) 22 (7) 32 (7) 
Education**    
   Less than high school 3 (2) 1 (<1) 4 (<1) 
   High school graduate 13 (8) 40 (13) 53 (11) 
   Some college or university 51 (30) 119 (38) 170 (35) 
   College graduate or higher 103 (60) 149 (47) 252 (52) 
   Unknown or refused 0 (0) 1(<1) 1 (<1) 
Family History of Cancer    
Average number of FDR with any cancer other than 
colorectal** 0.68 1.53 1.23 
Average number of FDR with colorectal cancer** 0.00 0.96 0.62 
Average number of SDR with any cancer, including 
colorectal 1.54 1.75 1.68 
Experience with a relative with cancer**    
Accompanied through diagnosis and treatment 22 (13) 109 (35) 131 (27) 
Spoke frequently about diagnosis/treatment but did not 
accompany 31 (18) 100 (32) 131 (27) 
Spoke occasionally about diagnosis/treatment 23 (13) 61 (20) 84 (18) 
Spoke very little about diagnosis/treatment 25 (15) 27 (9) 52 (11) 
Did not speak at all about diagnosis/treatment 40 (24) 11 (4) 51 (11) 
Refused 29 (17) 2 (<1) 31 (6) 
Self Assessment of Current Health    
EQ-5D summary score 0.878 0.889 0.885 
Visual Analogue Scale summary score (0-100 scale) 82.94 83.58 83.35 
Standard Gamble Utility Score    
Women 0.886 0.909 0.901 
Men 0.892 0.887 0.889 
All 0.889 0.901 0.896 
Estimate of lifetime colorectal cancer risk    
Age < 45 13% 29% 25% 
Age 46-55 8% 29% 23% 
Age 56-65 11% 21% 16% 
FDR = First degree relatives: parents, siblings, children  
SDR = Second degree relatives: grandparents, aunts, uncles 
** indicates significant difference between relatives and controls (p < 0.05) 
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Table 2. Self-Reported Screening and Lifestyle Behaviors of Respondents 
 
 
No Family 
History 
N=170 (%) 
Relatives 
N = 310 (%) 
Total  
N=480 (%) 
 
Screening (persons may list more than one 
procedure)** 
   
   FOBT last 2 years 49 (29) 67 (22) 116 (24) 
   Flexible sigmoidoscopy within 5 yrs 21 (12) 21 (7) 42 (9) 
   Colonoscopy within 5 yrs 58 (34) 172 (55) 230 (48) 
   No screening 70 (41) 88 (28) 158 (33) 
 
Healthy Diet    
  Healthy diet always  61 (36) 102 (33) 163 (34) 
  Healthy diet sometimes 106  (62) 197 (64) 303 (63) 
  Health diet rarely or never 1 (<1) 10 (3) 11  (2) 
  Refused 2 (1) 1 (<1) 3 (<1) 
 
Exercise Habits**    
  Exercise regularly or occasionally 138 (81) 246 (79) 384 (80) 
  Exercise rarely or never 30 (18) 63 (20) 93 (19) 
  Refused 2 (1) 1 (<1) 3 (<1) 
 
Lifestyle Habits 
   
Alcohol —drinks less than 1/day 151 (89) 270 (87) 421 (88) 
Smokes cigarettes, cigar 11 (7) 35 (11) 46 (10) 
FOBT = fecal occult blood test 
** indicates significant difference between relatives and controls (p < 0.05)
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Table 3. Participant responses to questions concerning anxiety/relief, exercise, diet, and 
screening behavior under a hypothetical scenario where they are told they are a colorectal 
cancer polymorphism carrier  
 
 
No 
Family 
History 
N=170 
(%) 
 
Relatives 
N = 310 (%) 
 
Both 
N=480 (%) 
 
 
Feelings of Worry    
  “Very” worried 24   (14) 61    (19) 85   (18) 
  “Somewhat” worried  121  (71) 208  (67) 329 (69) 
   No changes 23   (13) 39    (13) 62   (13) 
   Refused 2    (1) 2      (<1) 4     (<1) 
 
Feelings of worry one year after results    
  “Very” worried 13 (8) 46 (15) 59 (12) 
  “Somewhat” worried  121 (71) 214 (69) 335 (70) 
   No changes 33 (19) 47 (15) 80 (17) 
   Refused 3 (2) 3 (1) 6 (1) 
 
Informing others about a positive result    
  Would tell husband/wife/partner about result 151 (89) 269 (87) 420 (88) 
  Would tell siblings about result 114 (67) 240 (77) 354 (74) 
  Would tell children about result 95 (56) 168 (54) 263 (55) 
  Would tell parents about result 78 (46) 187 (60) 265 (55) 
  Would tell close friends about result 78 (46) 169 (55) 247 (52) 
  Would tell acquaintances about result 18 (11) 33 (11) 51 (11) 
  Would tell coworkers about result 14 (8) 43 (14) 57 (12) 
  Would tell no one about result 4 (2) 8 (3) 12 (3) 
  Total people told 552 1117 1669 
  Number of people told per respondent 3.25 3.60 3.48 
  Refused 3 2 5 
 
Changes in Exercise    
 Would exercise “a lot” more 35   (21) 84   (27) 119 (25) 
 Would exercise “a little” more 90   (53) 162 (52) 252 (53) 
 No changes 43   (25) 62   (20) 105 (22) 
 Exercise less    0         0       0 
 Refused 2     (1) 2     (<1) 4     (<1) 
 
Changes in Diet    
  “Big” changes 46 (27) 98   (32) 144 (30) 
  “A few” changes 110 (65) 185 (60) 295 (62) 
   No changes 12 (7) 26   (8) 38   (8) 
   Refused 2 (1) 1   (<1) 3   (<1) 
 
Intentions for Colorectal Cancer Screening**    
  Already screen regularly 73  (44) 171 (55) 244 (51) 
  Does not screen, would not change 4    (2) 6     (2) 10   (2) 
  Would start screening/adhere to doctor’s recommendation 85 (50) 119 (38) 204 (43) 
  Not sure 6 (3) 13 (4)   19(4) 
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  Refused 2 (1) 1 (<1) 3 (<1) 
** indicates significant difference between relatives and controls (p < 0.05). 
 
 
 
Table 4. Participant responses to questions concerning anxiety/relief, exercise, diet, and 
screening behavior under a hypothetical scenario where they are told they are a non-carrier of 
colorectal cancer polymorphism 
 
 
 
No Family History 
N=170 (%) 
Relatives 
N = 310 (%) 
Total   
N=480 (%) 
 
Feelings of Relief or Worry    
 “Very” worried 1 (<1) 0 1     (<1) 
 “Somewhat” worried 0 1 (<1) 1     (<1) 
  No changes 35 (21) 63 (20) 98   (20) 
 “A little” relieved 76 (45) 145 (47) 221 (46) 
“Somewhat” or “very” relieved 56 (33) 100 (32) 156 (33) 
  Refused 2 (1) 1 (<1) 3     (<1) 
 
Informing others about a negative result**    
  Would tell husband/wife/partner 141 (83) 266 (86) 407 (85) 
  Would tell siblings about a result 90 (53) 214 (69) 304 (63) 
  Would tell children about result 77 (45) 153 (49) 230 (48) 
  Would tell parents about result 63 (37) 173 (56) 236 (49) 
  Would tell close friends about result 59 (35) 129 (42) 188 (39) 
  Would tell acquaintances about result 12 (7) 28 (9) 40 (8) 
  Would tell coworkers about result 7 (4) 39 (13) 46 (10) 
  Would tell no one about result 13 (8) 13 (4) 26 (5) 
  Total people told 462 1015 1477 
  Number of people told per respondent 2.72 3.27 3.10 
  Refused 3 1 4 
 
Changes in Exercise    
  “A lot” more 6     (3) 18   (6) 24   (5) 
  “A little” more 43   (25) 101 (33) 144 (30) 
   No changes 118 (70) 190 (61) 308 (64) 
   Exercise less            0              0             0 
   Refused 3     (2)    1  (<1) 4  (<1) 
 
Changes in Diet    
  “Big” changes 2     (1) 9 (3) 11 (2) 
  “A few” changes 59   (35) 121 (39) 180 (37) 
   No changes 107 (63) 179 (58) 286 (60) 
   Refused 2    (1) 1 (<1) 3 (<1) 
 
Intentions for Colorectal Cancer Screening    
  Already screen regularly 74 (44) 176 (57) 250 (52) 
  Does not screen, would not change 18 (11) 21   (7) 39   (8) 
  Would start screening/adhere to doctor’s   
  recommendation 
50 (29) 73   (23) 123 (26) 
  Not sure 26 (15) 39   (13) 65   (14) 
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  Refused 2   (1) 1     (<1) 3     (<1) 
** indicates significant difference between relatives and controls (p < 0.05). 
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